54 related articles for article (PubMed ID: 18097514)
1. The Specific Choice of Transrectal Ultrasound-Guided Prostate Biopsy Scheme Based on Prostate Specific Antigen and Prostate Specific Antigen Density.
Chen Y; Jiang X; Liu R; Zhang Z; Luo F; Qi S; Xu Y
Med Sci Monit; 2019 Aug; 25():6230-6235. PubMed ID: 31424055
[TBL] [Abstract][Full Text] [Related]
2. Low TIM3 expression indicates poor prognosis of metastatic prostate cancer and acts as an independent predictor of castration resistant status.
Wu J; Lin G; Zhu Y; Zhang H; Shi G; Shen Y; Zhu Y; Dai B; Ye D
Sci Rep; 2017 Aug; 7(1):8869. PubMed ID: 28827755
[TBL] [Abstract][Full Text] [Related]
3. Constitutively active AR-V7 plays an essential role in the development and progression of castration-resistant prostate cancer.
Qu Y; Dai B; Ye D; Kong Y; Chang K; Jia Z; Yang X; Zhang H; Zhu Y; Shi G
Sci Rep; 2015 Jan; 5():7654. PubMed ID: 25563505
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel with or without zoledronic acid for castration-resistant prostate cancer.
Pan Y; Jin H; Chen W; Yu Z; Ye T; Zheng Y; Weng Z; Wang F
Int Urol Nephrol; 2014 Dec; 46(12):2319-26. PubMed ID: 25224665
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in bone-targeted therapies of metastatic prostate cancer.
Deng X; He G; Liu J; Luo F; Peng X; Tang S; Gao Z; Lin Q; Keller JM; Yang T; Keller ET
Cancer Treat Rev; 2014 Jul; 40(6):730-8. PubMed ID: 24767837
[TBL] [Abstract][Full Text] [Related]
6. Prostate cancer in Asian men.
Ito K
Nat Rev Urol; 2014 Apr; 11(4):197-212. PubMed ID: 24595118
[TBL] [Abstract][Full Text] [Related]
7. miR-205 is frequently downregulated in prostate cancer and acts as a tumor suppressor by inhibiting tumor growth.
Wang N; Li Q; Feng NH; Cheng G; Guan ZL; Wang Y; Qin C; Yin CJ; Hua LX
Asian J Androl; 2013 Nov; 15(6):735-41. PubMed ID: 23974361
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors in Chinese patients with metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy.
Qu YY; Dai B; Kong YY; Ye DW; Yao XD; Zhang SL; Zhang HL; Ma CG; Yang WY
Asian J Androl; 2013 Jan; 15(1):110-5. PubMed ID: 23147466
[TBL] [Abstract][Full Text] [Related]
9. The results of transperineal versus transrectal prostate biopsy: a systematic review and meta-analysis.
Shen PF; Zhu YC; Wei WR; Li YZ; Yang J; Li YT; Li DM; Wang J; Zeng H
Asian J Androl; 2012 Mar; 14(2):310-5. PubMed ID: 22101942
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumor activity of curcumin against androgen-independent prostate cancer cells via inhibition of NF-κB and AP-1 pathway in vitro.
Liu S; Wang Z; Hu Z; Zeng X; Li Y; Su Y; Zhang C; Ye Z
J Huazhong Univ Sci Technolog Med Sci; 2011 Aug; 31(4):530. PubMed ID: 21823017
[TBL] [Abstract][Full Text] [Related]
11. Serum early prostate cancer antigen (EPCA) level and its association with disease progression in prostate cancer in a Chinese population.
Zhao Z; Ma W; Zeng G; Qi D; Ou L; Liang Y
PLoS One; 2011 May; 6(5):e19284. PubMed ID: 21559289
[TBL] [Abstract][Full Text] [Related]
12. Retrospective descriptive analysis of the physiological kinetics of prostate-specific antigen in men older than 75 years.
Sighinolfi MC; Micali S; De Stefani S; Cicero A; Cianci F; Giacometti M; Bianchi G
Asian J Androl; 2009 Jul; 11(4):493-7. PubMed ID: 19448643
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen half-life: a new predictor of progression-free survival and overall survival in Chinese prostate cancer patients.
Lin GW; Yao XD; Zhang SL; Dai B; Ma CG; Zhang HL; Shen YJ; Zhu Y; Zhu YP; Shi GH; Qin XJ; Ye DW
Asian J Androl; 2009 Jul; 11(4):443-50. PubMed ID: 19182820
[TBL] [Abstract][Full Text] [Related]
14. Individualized prostate biopsy strategy for Chinese patients with different prostate-specific antigen levels.
Dai B; Ye DW; Kong YY; Shen YJ; Wang BH
Asian J Androl; 2008 Mar; 10(2):325-31. PubMed ID: 18097514
[TBL] [Abstract][Full Text] [Related]
15. Extended 21-sample needle biopsy protocol for diagnosis of prostate cancer in 1000 consecutive patients.
Guichard G; Larré S; Gallina A; Lazar A; Faucon H; Chemama S; Allory Y; Patard JJ; Vordos D; Hoznek A; Yiou R; Salomon L; Abbou CC; de la Taille A
Eur Urol; 2007 Aug; 52(2):430-5. PubMed ID: 17412489
[TBL] [Abstract][Full Text] [Related]
16. Individualization of the biopsy protocol according to the prostate gland volume for prostate cancer detection.
Eskicorapci SY; Guliyev F; Akdogan B; Dogan HS; Ergen A; Ozen H
J Urol; 2005 May; 173(5):1536-40. PubMed ID: 15821481
[TBL] [Abstract][Full Text] [Related]
17. No reason for immediate repeat sextant biopsy after negative initial sextant biopsy in men with PSA level of 4.0 ng/mL or greater (ERSPC, Rotterdam).
Roobol MJ; van der Cruijsen IW; Schröder FH
Urology; 2004 May; 63(5):892-7; discussion 897-9. PubMed ID: 15134973
[TBL] [Abstract][Full Text] [Related]
18. Indications and timing for prostate biopsy, diagnosis of early stage prostate cancer and its definitive treatment: a clinical conundrum in the PSA era.
Punnen S; Nam RK
Surg Oncol; 2009 Sep; 18(3):192-9. PubMed ID: 19282170
[TBL] [Abstract][Full Text] [Related]
19. The impact of reducing the prostate-specific antigen threshold and including isoform reflex tests on the performance characteristics of a prostate-cancer detection programme.
Roddam AW; Hamdy FC; Allen NE; Price CP;
BJU Int; 2007 Sep; 100(3):514-7. PubMed ID: 17542987
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
